Estudio de pembrolizumab frente a placebo en participantes con carcinoma esofágico que reciben quimioterapia y radioterapia
The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to